Document is current
Any future updates will be listed below
-
Authors
Guijarro, D. https://orcid.org/0000-0002-3202-9831
Jobbe-Duval, A.
Aguilhon, S.
Bauer, F.
Donal, E.
Eicher, J. C.
Jeanneteau, J.
Gellen, B.
Kenizou, D.
Lairez, O.
Lequeux, B.
Legallois, D.
Réant, P.
Salvat, M.
Seronde, M. F.
Kharoubi, M.
Whereat, A.
Farrugia, A.
Taieb, C.
Zaroui, A.
Damy, T.
- License Information
-
More Information
Article History
Received: 2 August 2024
Accepted: 13 June 2025
First Online: 8 July 2025
Declarations
:
: Ethics committee approval was not obtained considering the urgency of the situation and that the anonymous surveys about patient opinions that do not involve any medical procedures are tolerated under French law.
: Not applicable.
: TD has received grant and/or consulting fees from: AKCEA, Alnylam, Alexion, Bridge Bio, Pfizer, Neurimmune. DL reports honoraria for presentations and consulting fees from AstraZeneca, Boehringer Ingelheim, Lilly, Pfizer, and Takeda, outside of the submitted work. OL has received consulting fees from Alnylam, AstraZeneca and Pfizer. DG and AJD have received consulting fees from Alnylam, Pfizer. The other authors have no funding source to declare.
